Fargo, ND August 17 2023 – RxE2 announces the appointment of Doug Liberi as VP of Business Development and Sales.
In his role as VP of business development, Mr. Liberi will be in charge of category creation and market expansion for RxE2, leading the company’s sales team strategically.
“I am happy Doug has agreed to join us”, says Gerald Finken, CEO of RxE2. “His experience and passion will help shape RxE2’s expansion strategy, supporting our roadmap for continued growth”.
Mr. Liberi is bringing with him over 15 years of experience in the clinical research space at startups in a variety of leadership roles. He began his career in 2008 at YPrime, a startup eclinical consulting firm, and as part of the leadership team helped drive the company’s evolution from a consultancy to a market-leading eclinical software solutions provider with a portfolio of products including IRT, eCOA & CTMS. In 2019, Doug joined Medable as Head of Account Management where he led the growth of strategic accounts in the DCT space while providing oversight to the operational delivery teams. During his time at Medable, he contributed to the product strategy for DCT solutions with a focus on global regulations and user experience. With a proven track record of operational excellence and overall business growth, Doug is focused on category creation and market expansion.
“I wholeheartedly believe that RxE2 holds the key to the evolutionary leap in the clinical research sector. They understand that human engagement and trust are the missing ingredient from pure technology platforms”, said Mr. Liberi. “That is not to say RxE2 neglects the technology aspect. If anything, they found the perfect formula for utilizing the most advanced technology better than anyone, by putting it in the hands of the right people at the right time”.
About RxE2
RxE2 is the first company to make community-based decentralized clinical trials a cost-effective reality. By integrating the practice of pharmacy into every aspect of clinical trials, RxE2 empowers community pharmacists, as trusted medication experts, to use their extensive patient insights to make clinical trials more accessible for everyone, everywhere, to vastly reduce clinical trial timelines and costs, and to help study sponsors and patients alike achieve higher quality outcomes.
